PacBio (PACB) announced the publication of a new preprint from the HiFi Solves EMEA Consortium, “HiFi sequencing accurately identifies clinically relevant variants in paralogous genes.” The study shows that PacBio HiFi sequencing combined with Paraphase, a haplotype-based variant caller, uncovered all known clinically relevant variants present in the study population. From five institutions across Europe, in a cohort of 86 individuals carrying 125 known pathogenic variants across 11 complex genomic regions, HiFi sequencing combined with Paraphase detected all 125 clinically relevant variants in the study. The work represents the strongest validation to date of HiFi Solves’ founding goal: to show that high-accuracy long reads can bridge today’s research with tomorrow’s clinical utility.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- PacBio supports Berry Genomics in achieving approval for sequencer in China
- PACB Upcoming Earnings Report: What to Expect?
- Cathie Wood Cuts Stakes in AMD and Palantir (PLTR) Stocks, Loads Up on Deere and Pacific Biosciences
- Cathie Wood’s ARK Investment buys 633K shares of PacBio today
- Cathie Wood Boosts Biotech and DraftKings Stakes, Trims Shopify
